在手术期间评估一种新型多糖血静系统的安全性和有效性:一个多中心多专业前性随机对照试验
Michael G House1, Robin Kim2, Elaine E Tseng3
1Indiana University, Indianapolis, IN, United States of America.
Surgery open science
|May 27, 2024
概括
一种新的多糖血静剂 (PH) 产品被证明在手术出血控制方面与微孔多糖血球 (MPH) 不逊色. 这种研究药物在各种手术过程中显示出可比的安全性和有效性.
科学领域:
- 手术创新 在外科创新.
- 生物材料在医学中的应用
- 血液静止研究 血液静止研究
背景情况:
- 手术后出血增加了手术发病率和死亡率.
- 静血剂是控制手术内出血的关键辅助剂.
- 评估新型血液静止产品对于改善手术结果至关重要.
研究的目的:
- 评估试验中的多糖血静剂 (PH) 产品的安全性和有效性.
- 为了比较PH与美国FDA批准的对照物质,微孔多糖胺血球 (MPH).
- 为了确定PH在手术期间实现血液静止的有效性.
主要方法:
- 一个前性的多中心随机试验,比较PH和MPH.
- 接受心脏,一般性或泌尿外科手术的患者被纳入.
- 主要终点:7分钟后血静的PH与MPH的非劣势.
主要成果:
- PH显示不低于MPH,满足了初级静血终点.
- 在PH和MPH之间没有观察到不良事件发生率的显著差异.
- 在瘤学患者中,PH和MPH的2年整体存活率相似.
结论:
- 多糖血静性 (PH) 产品与微孔多糖血球 (MPH) 没有劣势.
- PH没有显示安全问题,是有效的静血替代品.
- 这项研究支持PH作为手术静血的可行选择.
相关概念视频
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...


